Items tagged with Access
TAG policy brief: Advancing Access through Market Interventions (post with simple image)
Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down
Public investment in bedaquiline up to five-fold that of Johnson & Johnson (post with simple image)
PLOS ONE publishes TAG’s rigorous, peer-reviewed calculation of investments in the development of this life-saving TB medicine.
Paediatric HIV & TB: Rome Action Plan (post with simple image)
EGPAF, WHO, PEPFAR, UNAIDS, Stop TB Partnership and FBOs: World Children’s Day statement on advances in access to paediatric HIV and TB diagnosis and treatments
A Deadly Divide: TB Commitments vs. TB Realities (post with simple image)
A communities report on progress towards the UN Political Declaration on the Fight Against TB and a Call to Action to close the gaps in TB targets
‘Catastrophic moral failure’: Stop TB Partnership joins WHO Director-General’s warning on COVID-19 vaccines (post with simple image)
Lack of access to COVID-19 vaccines for people in the world’s poorest countries echoes the health inequity faced by people affected by TB.
Activists call on Indian government to revitalize the TB preventive treatment program (post with simple image)
Indian activists demand the introduction of the newer short-course TB preventive treatment regimens for people living with HIV.
Advocates request Cepheid increase access to GeneXpert SARS-CoV-2 tests in LMICs (post with simple image)
Advocates demand Cepheid commit a greater proportion of its COVID-19 manufacturing capacity to LMICs and lower the price of its cartridges to $5.
5 things we learned in taking on big pharma (post with simple image)
“Medicines shouldn’t be a luxury”: For over ten years, I have been working with inspiring teams around the globe creating and coordinating public campaigns that ignite people’s imaginations and change lives.
Time for $5 Coalition statement: Cepheid’s updated GeneXpert pricing does not address country needs (post with simple image)
The Time for $5 Coalition calls out Cepheid for not including price reductions of Xpert tests in their updated GeneXpert pricing packages for low- and middle-income countries.
Substantial public investments in GeneXpert underscore need for affordable pricing (post with simple image)
PLOS ONE publishes TAG’s comprehensive analysis of public investments in the development of rapid technology for diagnosing infectious diseases.
Page 76 of 83 · Total posts: 0
←First 75 76 77 Last→